Comparison 9. RISPERIDONE versus OLANZAPINE - sensitivity analysis (skewed data excluded).

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state: 1a. General - average endpoint score (PANSS total, high = poor)	14	2348	Mean Difference (IV, Random, 95% CI)	1.99 [0.60, 3.37]
1.1 short term	6	686	Mean Difference (IV, Random, 95% CI)	1.02 [−1.11, 3.15]
1.2 medium term	3	231	Mean Difference (IV, Random, 95% CI)	4.11 [−0.71, 8.93]
1.3 long term	5	1431	Mean Difference (IV, Random, 95% CI)	2.59 [0.20, 4.98]
2 Mental state: 2. General - average endpoint score (BPRS total, high = poor)	2	393	Mean Difference (IV, Random, 95% CI)	4.28 [−1.34, 9.91]
2.1 Long term	2	393	Mean Difference (IV, Random, 95% CI)	4.28 [−1.34, 9.91]
3 Mental state: 3. Positive symptoms - average endpoint score (PANSS positive, high = poor)	12	1663	Mean Difference (IV, Random, 95% CI)	0.62 [0.03, 1.21]
3.1 short term	4	622	Mean Difference (IV, Random, 95% CI)	−0.28 [−1.62, 1.07]
3.2 medium term	3	231	Mean Difference (IV, Random, 95% CI)	1.58 [−0.03, 3.20]
3.3 long term	5	810	Mean Difference (IV, Random, 95% CI)	0.68 [−0.04, 1.40]
4 Adverse effects: 1. Extrapyramidal effects - scale measured	7		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1 dyskinesia: ESRS subscore for dyskinesia (high = poor)	2	401	Mean Difference (IV, Random, 95% CI)	0.10 [−0.42, 0.62]
4.2 extrapyramidal symptoms: ESRS total score (high = poor)	2	530	Mean Difference (IV, Random, 95% CI)	0.16 [−0.58, 0.90]
4.3 extrapyramidal symptoms: Simpson-Angus Scale (high = poor)	4	487	Mean Difference (IV, Random, 95% CI)	0.75 [−0.10, 1.59]
4.4 parkinsonism: ESRS subscore for parkinsonism (high = poor)	2	401	Mean Difference (IV, Random, 95% CI)	1.06 [−1.31, 3.42]
5 Adverse effects: 2. Prolactin associated side effects - change from baseline in ng/ml	5		Mean Difference (IV, Random, 95% CI)	Subtotals only
5.1 change from baseline in ng/ml	5	1256	Mean Difference (IV, Random, 95% CI)	24.70 [21.08, 28.33]